Jeffrey Trigilio

Jeffrey Trigilio is a seasoned finance executive with extensive experience in the biotechnology and pharmaceutical sectors. Currently serving as Chief Financial Officer at Obsidian Therapeutics since April 2024, Jeffrey Trigilio previously held the same position at Amylyx Pharmaceuticals and worked as a Consultant Chief Financial Officer at Cullinan Therapeutics. Prior roles include Vice President of Corporate Finance at BlueRock Therapeutics and various financial leadership positions at Alexion Pharmaceuticals and RBC Capital Markets, showcasing expertise in strategic decision analysis, corporate planning, and investment banking. Jeffrey Trigilio holds an MBA from Columbia Business School and a Bachelor’s Degree in Industrial and Labor Relations from Cornell University.